Press release
Uremic Pruritus Market is Expected to Reach USD 3.2 Billion by 2034
Uremic Pruritus
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71545
Recent advancements in targeted therapies, especially kappa opioid receptor agonists, have changed the treatment landscape. Combined with rising awareness among nephrologists and growing dialysis populations, the UP market is poised for steady expansion between 2024 and 2034.
Market Overview
The global uremic pruritus (UP) market size in 2024 is estimated at USD 1.5 billion and is projected to reach USD 3.2 billion by 2034, growing at a CAGR of 9% over the forecast period.
Key highlights:
• Rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD).
• Growing adoption of novel therapies such as difelikefalin (KORSUVATM) and other kappa opioid receptor agonists.
• Increasing focus on patient-reported outcomes and quality-of-life measures.
• Strong support from patient advocacy groups and clinical research initiatives.
• North America and Europe lead today, while Asia-Pacific is expected to see the highest patient pool growth.
Market Segmentation
By Product
• Antihistamines
• Emollients & Moisturizers
• Gabapentinoids (Gabapentin, Pregabalin)
• Kappa Opioid Receptor Agonists (Difelikefalin, Others)
• Corticosteroids
• Others
By Technology
• Small-Molecule Drugs
• Biologics & Monoclonal Antibodies
• Topical & Systemic Therapies
• Digital Health & Patient Monitoring Platforms
By Platform
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End Use
• Hospitals & Specialty Clinics
• Dialysis Centers
• Homecare Settings
• Research & Academic Institutes
By Application
• Hemodialysis Patients
• Peritoneal Dialysis Patients
• Pre-Dialysis CKD Patients
Summary of Segmentation
Kappa opioid receptor agonists are driving market growth as the first targeted therapy for UP, while antihistamines and emollients remain widely used in mild cases. Dialysis centers dominate the application segment, given the high prevalence of UP among ESRD patients undergoing hemodialysis.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71545/uremic-pruritus-up-market
Regional Analysis
North America
• Largest market in 2024 due to high ESRD prevalence, advanced nephrology infrastructure, and rapid uptake of novel therapies like difelikefalin.
• U.S. leads clinical research and patient advocacy initiatives.
Europe
• Second-largest market, with strong contributions from Germany, the UK, France, and Italy.
• Widespread adoption of dialysis treatments and reimbursement support for UP therapies.
Asia-Pacific
• Expected to grow at the fastest CAGR through 2034.
• Large CKD and ESRD patient pools in China, India, and Japan.
• Expanding dialysis infrastructure and increasing awareness of UP's impact on patient quality of life.
Middle East & Africa
• Gradual growth driven by improving healthcare access and rising dialysis prevalence.
• Still limited by low awareness and underdiagnosis.
Latin America
• Brazil and Mexico dominate the region, with expanding dialysis programs and growing adoption of new therapies.
Regional Summary
North America and Europe lead adoption today, but Asia-Pacific is projected to drive the fastest growth due to its large dialysis population and expanding healthcare systems.
Market Dynamics
Growth Drivers
• Rising global prevalence of CKD and ESRD.
• Increasing availability of novel therapies like difelikefalin.
• Growing awareness among nephrologists about the burden of UP.
• Focus on quality-of-life outcomes in CKD management.
Key Challenges
• High costs of novel therapies, limiting adoption in emerging economies.
• Limited awareness among primary care providers.
• Reliance on symptomatic management with low efficacy in some patients.
• Uneven access to advanced nephrology care globally.
Latest Trends
• Expansion of kappa opioid receptor agonists beyond dialysis patients into earlier CKD stages.
• Use of digital health platforms for patient-reported outcome monitoring.
• Increasing clinical research into biologic therapies targeting itch pathways.
• Growing patient advocacy and rare disease collaborations in nephrology.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71545
Competitive Landscape
Major Players
• Cara Therapeutics (Difelikefalin - KORSUVATM)
• Vifor Pharma
• CSL Vifor
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Sanofi S.A.
• Johnson & Johnson
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Dr. Reddy's Laboratories
Competition Summary
Cara Therapeutics leads the UP market with its novel kappa opioid receptor agonist, difelikefalin. Other major pharma players are exploring biologics and small molecules for symptom control. Competition is expected to intensify as biosimilars, generics, and new targeted therapies enter the market, especially in Asia-Pacific and Latin America.
Conclusion
The uremic pruritus market is poised for steady expansion through 2034, driven by the global rise in CKD and ESRD, new therapeutic launches, and increasing focus on patient quality of life.
While high costs and limited awareness remain challenges, opportunities exist in emerging economies, digital health integration, and expansion of novel therapies beyond dialysis patients. For pharmaceutical companies, dialysis providers, and healthcare systems, UP represents both an unmet medical need and a growing commercial opportunity.
Key Takeaways:
• Rising CKD and ESRD prevalence is driving UP market growth.
• Difelikefalin and other kappa opioid receptor agonists are reshaping treatment paradigms.
• North America and Europe lead today, while Asia-Pacific will record the fastest growth.
• Innovation, affordability, and expanded access will define long-term success.
This report is also available in the following languages : Japanese (尿毒症性掻痒症(UP)市場), Korean (요독성 가려움증(UP) 시장), Chinese (尿毒症瘙痒症(UP)市场), French (Marché du prurit urémique (UP)), German (Markt für urämischen Pruritus (UP)), and Italian (Mercato del prurito uremico (UP)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71545/uremic-pruritus-up-market#request-a-sample
Our More Reports:
Multiple System Atrophy (MSA) Market
https://exactitudeconsultancy.com/reports/71911/multiple-system-atrophy-msa-market
Neuromyelitis Optica Market
https://exactitudeconsultancy.com/reports/71912/neuromyelitis-optica-market
Obsessive Compulsive Disorder Market
https://exactitudeconsultancy.com/reports/71913/obsessive-compulsive-disorder-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uremic Pruritus Market is Expected to Reach USD 3.2 Billion by 2034 here
News-ID: 4170187 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for CKD
Chronic Kidney Disease (CKD) Key Players, Share and Forecast Outlook
Chronic Kidney Disease (CKD) is a long-term medical condition characterized by a gradual decline in kidney function over time. CKD often leads to complications such as anemia, cardiovascular disease, and end-stage renal disease (ESRD), which necessitate dialysis or kidney transplant.
With rising global cases of diabetes, hypertension, and aging populations, the demand for effective CKD management solutions has significantly grown. The CKD market, valued at USD 74.54 billion in 2024, is…
Nephrology Drugs Market Booming Worldwide with Rising CKD Prevalence | AstraZene …
Nephrology Drugs Market Snapshot
The Nephrology Drugs Market is projected to grow from USD 14.32 billion in 2024 to USD 21.01 billion by 2032, at a CAGR of 4.91% during the forecast period.
Coherent Market Insights proudly presents its latest Nephrology Drugs Market Research Report, delivering a detailed examination of the U.S. Nephrology Drugs Market outlook from 2025 to 2032. This comprehensive analysis provides strategic forecasts at both national and regional levels,…
Chronic Kidney Disease (CKD) Market CAGR: Growth, Share, Value, Size, and Analys …
Chronic Kidney Disease (CKD) Market Size And Forecast by 2030
Data Bridge Market Research analyses that the Global Chronic Kidney Disease (CKD) Market which was USD 13220 Billion in 2022 is expected to reach USD 18800.17 Million by 2030 and is expected to undergo a CAGR of 4.50% during the forecast period of 2022 to 2030
Explore Further Details about This Research Chronic Kidney Disease (CKD) Market Report https://www.databridgemarketresearch.com/reports/global-chronic-kidney-disease-ckd-market
**Segments**
- **Type of CKD:**…
Chronic Kidney Disease (CKD) Drugs Market- Boosting the Healthcare Industry Worl …
The global Chronic Kidney Disease (CKD) Drugs market is estimated to attain a valuation of USD 15.8 bn by the end of 2024, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 3.6% during the forecast period, 2016 - 2024.
The key objective of the TMR report is to offer a complete assessment of the global market…
Semiconductor Air Cylinder Market: Players tapping Emerging Markets |Festo, SMC, …
Latest Study on Semiconductor Air Cylinder Market 2022-2028. A detailed study accumulated to offer Latest insights about acute features of the Semiconductor Air Cylinder market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, Growth Opportunities, Market Trend and Technologies, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends…
Railway Valves Market global outlook and forecast 2021 -2027|Norgren ,CKD
The Global Railway Valves Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Railway Valves makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise spins around the most powerful…
